Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects

Trial Profile

Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CheckMate 205
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Nov 2019 Results of MAIC analysis (matching adjusted indirect comparison) of two clinical trials CheckMate 205 or NCT02181738 (n=306) and NCT00848926 (n=102) assesing efficacy and survival benefit of nivolumab relative to Brentuximab vedotin in relapsed/refractory classical hodgkin lymphoma, released in 61st Annual Meeting and Exposition of the American Society of Hematology
    • 16 May 2019 According to a Bristol-Myers Squibb Media Release, data from this trial will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago, May 31-June 4, and the 24th Annual Congress of the European Hematology Association (EHA) in Amsterdam, June 13-16.
    • 12 May 2019 Results of cohort D of this trial (n=51, patients untreated, advanced-stage (defined as III to IV and IIB with unfavorable risk factors) Classic Hodgkin Lymphoma ) published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top